|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Atara Biotherapeutics, Inc. (ATRA) |
|
|
$0.39 0.00 (0.00%) as of 4:30 Tue 6/18
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
108,674,000 |
Market
Cap: |
42.88(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2298 - $2.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 707 |
Guru Rank Value : 1.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
4 |
4 |
Total Shares Sold |
211,204 |
267,396 |
419,842 |
591,605 |
Total Sell Value |
$130,313 |
$170,773 |
$340,560 |
$980,941 |
Total People Sold |
5 |
5 |
6 |
9 |
Total Sell Transactions |
5 |
10 |
23 |
41 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,082 |
35,625 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-05-15 |
4 |
D |
$37.30 |
$70,385 |
D/D |
(1,887) |
264,165 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,422 |
266,052 |
|
- |
|
Mcgrath John |
Chief Financial Officer |
|
2015-05-15 |
4 |
D |
$37.30 |
$1,134,107 |
D/D |
(30,405) |
47,352 |
|
- |
|
Mcgrath John |
Chief Financial Officer |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,357 |
77,757 |
|
- |
|
Fust Matthew K |
Director |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,478 |
7,478 |
|
- |
|
Soffer Gad |
Chief Operating Officer |
|
2015-05-15 |
4 |
D |
$37.30 |
$1,822,142 |
D/D |
(48,851) |
65,788 |
|
- |
|
Soffer Gad |
Chief Operating Officer |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,239 |
114,639 |
|
- |
|
Clark Mitchall G. |
Chief R & QA Officer |
|
2015-05-15 |
4 |
D |
$37.30 |
$487,362 |
D/D |
(13,066) |
30,584 |
|
- |
|
Clark Mitchall G. |
Chief R & QA Officer |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
43,650 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-15 |
4 |
D |
$37.30 |
$552,077 |
D/D |
(14,801) |
54,707 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,508 |
69,508 |
|
- |
|
Seidenberg Beth C |
Director |
|
2015-05-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(266,022) |
71,822 |
|
- |
|
Kpcb Xv Founders Fund, Llc |
10% Owner |
|
2015-05-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(200,000) |
71,822 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-04-23 |
4 |
AS |
$62.70 |
$163,020 |
I/I |
(2,600) |
392,300 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-04-22 |
4 |
AS |
$60.01 |
$156,026 |
I/I |
(2,600) |
394,900 |
|
- |
|
Marcus Joel S |
Director |
|
2015-03-10 |
4 |
B |
$29.99 |
$44,985 |
I/I |
1,500 |
4,000 |
2.1 |
- |
|
Marcus Joel S |
Director |
|
2015-03-09 |
4 |
B |
$29.32 |
$73,300 |
I/I |
2,500 |
2,500 |
2.1 |
- |
|
Gallagher Carol Giltner |
Director |
|
2015-02-18 |
4 |
B |
$18.00 |
$198,000 |
I/I |
11,000 |
62,656 |
2.1 |
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
38,000 |
|
- |
|
Clark Mitchall G. |
Chief R & QA Officer |
|
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,400 |
12,400 |
|
- |
|
Mcgrath John |
Chief Financial Officer |
|
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,400 |
12,400 |
|
- |
|
Soffer Gad |
Chief Operating Officer |
|
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,400 |
12,400 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,400 |
261,630 |
|
- |
|
Marcus Joel S |
Director |
|
2014-10-21 |
4/A |
B |
$11.00 |
$99,990 |
D/D |
9,090 |
9,090 |
2.39 |
- |
|
736 Records found
|
|
Page 29 of 30 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|